Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actos' Bladder Cancer Signal May Hinge On Dose, Duration Of Use

This article was originally published in The Pink Sheet Daily

Executive Summary

A five-year interim analysis of a 10-year epidemiological study showed no significant overall increased risk between exposure to Takeda's pioglitazone and bladder cancer, although an increased risk was seen among patients with the highest cumulative dose and the longest duration of exposure.
Advertisement

Related Content

Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
First-In-Class Dapaglifozin Headed For FDA Advisory Committee Review
Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety
Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says
Avandia Can Be Saved With New Warnings and REMS, Advisory Cmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS071188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel